COMP <GO>
RLMD vs CAPR // EV/EBITDA & P/E VALUATION
Relmada Therapeutics Inc. (NASDAQ) VS. Capricor Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: RLMD 2
— CAPR 2
■ METRIC PARITY
LAST: $3.44 (+2.69%) • MKT CAP: $366.9M
valuation
—
LAST: $6.63 (+6.42%) • MKT CAP: $385.5M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RLMD VS. CAPR)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RLMD | CAPR | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -12.48% | -18.86% | +6.38 | RLMD | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 3.38 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | 2/9 | -1.00 | CAPR | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.9 | 41.6 | +11.30 | RLMD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $366.9M | $385.5M | -$18.5M | CAPR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RLMD REV | CAPR REV | RLMD GROSS % | CAPR GROSS % | RLMD FCF | CAPR FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$45.8M | -$72.7M |
| FY 2024 | $0 | $22.3M | — | — | -$51.8M | -$41.2M |
| FY 2023 | — | $25.2M | — | — | — | -$25.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RLMD // BETA —
CAPR // BETA —